View our archive of investor presentations, annual and interim reports from 4D pharma plc (NASDAQ: LBPS; AIM: DDDD)
Corporate Presentation
Annual Reports & Interims
| Date | 2019 May 28 |
|---|---|
| Title | Annual report for the year ended 31 December 2018 |
| Document | (4,255KB) |
| Link | — |
| Date | 2018 Sep 28 |
| Title | Interim results for the period ended 30 June 2018 |
| Document | (269KB) |
| Link | visit |
| Date | 2018 Apr 25 |
| Title | Annual report for the year ended 31 December 2017 |
| Document | (1,369KB) |
| Link | — |
| Date | 2017 Sep 27 |
| Title | Interim results for the period ended 30 June 2017 |
| Document | (2,820KB) |
| Link | — |
| Date | 2017 May 02 |
| Title | Annual report for the year ended 31 December 2016 |
| Document | (3,262KB) |
| Link | — |
| Date | 2016 Sep 30 |
| Title | Interim results for the period ended 30 June 2016 |
| Document | — |
| Link | visit |
| Date | 2016 May 06 |
| Title | Annual report for the year ended 31 December 2015 |
| Document | (771KB) |
| Link | — |
| Date | 2015 Sep 29 |
| Title | Interim results for the period ended 30 June 2015 |
| Document | (429KB) |
| Link | — |
| Date | 2015 May 06 |
| Title | Annual Report for the year ended 31 December 2014 |
| Document | (659KB) |
| Link | — |
| Date | 2014 Sep 23 |
| Title | Interim results for the period ended 30 June 2014 |
| Document | — |
| Link | visit |
View RNS announcements
Subscribe to RNS email alerts
For any enquiries please contact [email protected]
Past Events & Presentations
KOL Event: MRx0518 SITC 2020 data, 11 November 2020
On Wednesday 11 November 13:00 GMT (08:00 ET), 4D pharma CEO Duncan Peyton and CSO Alex Stevenson are joined by Dr Mark P Lythgoe, Academic Clinical Fellow in Medical Oncology and Pharmacist at Imperial College London, and Dr Shubham Pant, Associate Professor Department of Investigational Cancer Therapeutics and Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, to discuss immuno-oncology LBP MRx0518 monotherapy and checkpoint inhibitor combination data published at SITC 2020.
To replay the call, visit https://wsw.com/webcast/cc/dddd.l/ and you can download the accompanying slides here.
R&D; Webinar: Blautix® BHT-II-002 IBS Phase II, 7 October 2020
CSO Dr. Alex Stevenson discusses the results of the BHT-II-002 Phase II trial of Live Biotherapeutic Blautix for the treatment of both IBS-C and IBS-D. He is joined by CEO Duncan Peyton, and CBO Glenn Dourado. Followed by analyst Q&A; session.
View the webinar below, and download the presentation slides and a transcript
R&D; Webinar: MicroRx® platform, 1 September 2020
4D pharma's Research Director Dr Imke Mulder hosts a webinar discussing 4D's world-leading Live Biotherapeutic discovery platform MicroRx®. Imke is joined by Alex Stevenson, CSO, and senior members of the Research team. The presentation is followed by a Q&A; session with analysts
View the webinar below, and download the presentation slides and a transcript of the audio
R&D; Webinar Clinical Update: Oncology & COVID-19, 5 June 2020
4D's Chairman, CEO and CSO host a virtual R&D; event providing an update on the Company's clinical programs in oncology and COVID-19, including a Q&A; with covering analysts
You can download the presentation slides and a transcript of the audio
